KRYS Stock Overview
A commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Krystal Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$169.25 |
| 52 Week High | US$189.97 |
| 52 Week Low | US$93.95 |
| Beta | 0.90 |
| 1 Month Change | 7.63% |
| 3 Month Change | 51.17% |
| 1 Year Change | 42.79% |
| 3 Year Change | 154.66% |
| 5 Year Change | 436.11% |
| Change since IPO | 1,490.70% |
Recent News & Updates
Recent updates
Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think
May 13
Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?
Aug 08We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30Krystal Biotech cleared to file EU marketing application for rare skin disease therapy
Sep 22We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30Krystal Biotech: Solid Performance, Let's Keep Holding
Aug 18Krystal Biotech GAAP EPS of -$1.10 misses by $0.07
Aug 08Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis
Aug 01Krystal Biotech: High Potential, Buy-At-Dips Stock
May 25We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Krystal Biotech: The Future Looks More And More Derisked
Feb 21Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications
Nov 30Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout
Sep 27Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Sep 25Companies Like Krystal Biotech (NASDAQ:KRYS) Are In A Position To Invest In Growth
Jun 17Krystal Biotech EPS misses by $0.16
May 10Krystal Biotech provides update on pivotal GEM-3 study of B-VEC for DEB
Apr 26Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Mar 02Krystal Biotech secures $125 capital via equity raise
Feb 03Shareholder Returns
| KRYS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.7% | 0.7% | 1.2% |
| 1Y | 42.8% | 5.0% | 27.7% |
Return vs Industry: KRYS exceeded the US Biotechs industry which returned 5% over the past year.
Return vs Market: KRYS exceeded the US Market which returned 27.7% over the past year.
Price Volatility
| KRYS volatility | |
|---|---|
| KRYS Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: KRYS's share price has been volatile over the past 3 months.
Volatility Over Time: KRYS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 229 | Krish Krishnan | www.krystalbio.com |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
Krystal Biotech, Inc. Fundamentals Summary
| KRYS fundamental statistics | |
|---|---|
| Market cap | US$4.76b |
| Earnings (TTM) | US$57.16m |
| Revenue (TTM) | US$95.95m |
84.6x
P/E Ratio50.4x
P/S RatioIs KRYS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRYS income statement (TTM) | |
|---|---|
| Revenue | US$95.95m |
| Cost of Revenue | US$5.51m |
| Gross Profit | US$90.44m |
| Other Expenses | US$33.28m |
| Earnings | US$57.16m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.00 |
| Gross Margin | 94.25% |
| Net Profit Margin | 59.57% |
| Debt/Equity Ratio | 0% |
How did KRYS perform over the long term?
See historical performance and comparison